DE69837551D1 - Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen - Google Patents

Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen

Info

Publication number
DE69837551D1
DE69837551D1 DE69837551T DE69837551T DE69837551D1 DE 69837551 D1 DE69837551 D1 DE 69837551D1 DE 69837551 T DE69837551 T DE 69837551T DE 69837551 T DE69837551 T DE 69837551T DE 69837551 D1 DE69837551 D1 DE 69837551D1
Authority
DE
Germany
Prior art keywords
disease
fibrils
amyloidoses
composition
treating alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837551T
Other languages
English (en)
Other versions
DE69837551T2 (de
Inventor
Gerardo Castillo
Alan D Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21944344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69837551(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Washington filed Critical University of Washington
Application granted granted Critical
Publication of DE69837551D1 publication Critical patent/DE69837551D1/de
Publication of DE69837551T2 publication Critical patent/DE69837551T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69837551T 1997-05-15 1998-05-15 Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen Expired - Lifetime DE69837551T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4660297P 1997-05-15 1997-05-15
US46602P 1997-05-15
PCT/US1998/010239 WO1998051302A1 (en) 1997-05-15 1998-05-15 Composition and methods for treating alzheimer's disease and other amyloidoses

Publications (2)

Publication Number Publication Date
DE69837551D1 true DE69837551D1 (de) 2007-05-24
DE69837551T2 DE69837551T2 (de) 2007-12-20

Family

ID=21944344

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837551T Expired - Lifetime DE69837551T2 (de) 1997-05-15 1998-05-15 Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen

Country Status (10)

Country Link
US (5) US6939570B1 (de)
EP (1) EP1019044B1 (de)
JP (1) JP4386470B2 (de)
AT (1) ATE359071T1 (de)
AU (1) AU7580098A (de)
CA (1) CA2289531C (de)
DE (1) DE69837551T2 (de)
DK (1) DK1019044T3 (de)
ES (1) ES2285772T3 (de)
WO (1) WO1998051302A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6929808B2 (en) 2000-11-03 2005-08-16 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
US20030017998A1 (en) * 1997-05-16 2003-01-23 Snow Alan D. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP1019044B1 (de) * 1997-05-15 2007-04-11 University of Washington Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
HUP0101693A3 (en) * 1998-03-26 2002-08-28 Phytopharm Plc Godmanchester Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease
CA2376008A1 (en) * 1999-06-02 2000-12-14 Oxford Natural Products Plc Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe
US6887898B1 (en) 1999-10-22 2005-05-03 Darrick S. H. L. Kim Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease
US7728043B2 (en) 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
WO2001030335A2 (en) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
JP3418724B2 (ja) * 2000-02-10 2003-06-23 国立医薬品食品衛生研究所長 セスキテルペノイド化合物及びそれを含む医薬
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
AU2002250117B2 (en) * 2001-03-15 2007-11-29 Cognitive Clarity Inc. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
WO2003013442A2 (en) * 2001-03-15 2003-02-20 Proteotech. Inc. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
SI1511710T1 (sl) * 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
AU2003279213B2 (en) * 2002-10-11 2008-12-18 Cognitive Clarity Inc. Isolation, purification and synthesis of procyanidin B2 and uses thereof
AU2004245567B2 (en) 2003-06-03 2011-06-23 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
EP1677801A4 (de) * 2003-10-10 2010-09-22 Sk Chemicals Co Ltd Wirksame triterpen-verbindungen zur verbesserung der hirnfunktion
DE102004018930A1 (de) * 2004-04-20 2005-11-17 Degussa Ag Verwendung eines keramischen Separators in Lithium-Ionenbatterien, die einen Elektrolyten aufweisen, der ionische Flüssigkeiten enthält
DK1746976T3 (en) 2004-05-03 2017-04-10 Merrimack Pharmaceuticals Inc LIPOSOMES SUITABLE FOR PHARMACEUTICAL SUPPLY
BRPI0403688A (pt) * 2004-09-01 2006-05-02 Herbarium Lab Botan Ltda composto fitoterápico tópico para tratamento de herpes
US7446210B2 (en) * 2004-10-26 2008-11-04 Janssen Pharmaceutica N.V. Factor Xa compounds
CH697330B1 (de) * 2004-12-28 2008-08-29 Synthes Gmbh Zwischenwirbelprothese.
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
US9279806B2 (en) 2005-04-22 2016-03-08 The Hong Kong University Of Science And Technology Water-soluble AIE luminogens for monitoring and retardation of fibrillation of amyloid proteins
US8679738B2 (en) 2005-04-22 2014-03-25 The Hong Kong University Of Science And Technology Water-soluble AIE luminogen for monitoring and retardation of amyloid fibrillation of insulin
CN101437503A (zh) * 2006-02-21 2009-05-20 阿斯特鲁姆医疗有限公司 用于降低血糖水平和治疗糖尿病的组合物
US8821851B2 (en) * 2006-03-23 2014-09-02 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
EP2240017B1 (de) 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketonkörper und ketonkörperester als blutfettsenkende mittel
ES2326065B1 (es) * 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
JP2011526925A (ja) * 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ，インク． ヘパラン硫酸阻害剤
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
JP5334508B2 (ja) * 2008-09-10 2013-11-06 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 高活性ｐｏａの製法
US8137666B2 (en) * 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
FR2941697A1 (fr) * 2009-02-02 2010-08-06 Pf Medicament Derives de tagitinine c et f comme agents anticancereux.
CN102548560B (zh) 2009-06-12 2016-01-20 基因雷克斯制药有限公司 用于预防和治疗冠心病的组合物和方法
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
AU2013337308B2 (en) 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
AU2014101153A4 (en) * 2014-01-03 2014-10-23 Macau University Of Science And Technology A Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof
JP6796072B2 (ja) 2015-02-27 2020-12-02 コグニティヴ クラリティ インコーポレイテッド ヒトおよび動物における「プラークおよびもつれ」の処置のための組成物と方法
AU2016340153B2 (en) 2015-10-16 2022-06-02 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US10946056B2 (en) 2016-09-16 2021-03-16 University Of South Florida Inhibition of formation of amyloid b-protein fibrils using cactus mucilage extracts
US10391135B2 (en) * 2016-09-16 2019-08-27 University Of South Florida Inhibition of formation of amyloid β-protein fibrils using cactus mucilage extracts
CN107397906A (zh) * 2017-08-24 2017-11-28 王小军 一种治疗继发性系统性淀粉样变的中药
US10799551B2 (en) * 2017-09-25 2020-10-13 Amorepacific Corporation Composition for enhancing cognitive function comprising green tea extract which has modified amounts of ingredients
US10098922B1 (en) * 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
JP7037814B2 (ja) * 2018-03-28 2022-03-17 国立大学法人山口大学 ホルボールエステルを有効成分とする軸索の伸展剤
JP2022512372A (ja) 2018-12-12 2022-02-03 コグニティヴ クラリティ インコーポレイテッド ヒトおよび動物における「プラークおよびタングル」の処置のための組成物および方法
KR102583195B1 (ko) * 2020-12-10 2023-09-26 경상국립대학교산학협력단 퀴노바산을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
KR102509211B1 (ko) * 2021-02-01 2023-03-10 가천대학교 산학협력단 이소미트라필린, 미트라필린, 또는 이들의 약제학적으로 허용 가능한 염을 포함하는 퇴행성 신경질환의 예방 또는 치료용 약제학적 조성물
CN113797204B (zh) * 2021-11-08 2023-07-28 辽宁大学 小檗胺在制备治疗阿尔兹海默症药物中的应用
US11883457B1 (en) 2022-09-06 2024-01-30 Optigenex Inc. Method of enhancing cognition in individuals with at least normal cognition
WO2024056498A1 (en) * 2022-09-12 2024-03-21 Société des Produits Nestlé S.A. Oxindole alkaloid derivatives as inhibitors of sglt2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE13012T1 (de) * 1980-10-07 1985-05-15 Klaus Keplinger Extract aus uncaria tomentosa (willd.) dc. zur therapeutischen verwendung.
US5302611A (en) 1980-10-07 1994-04-12 Klaus Keplinger Oxindole alkaloids having properties stimulating the immunologic system & preparation containing the same
US5166139A (en) 1987-02-26 1992-11-24 Indena, S.P.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
US6039949A (en) * 1997-02-27 2000-03-21 Campamed, Inc. Method of preparation and composition of a water soluble extract of the plant species uncaria
US6346280B1 (en) * 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
EP1019044B1 (de) * 1997-05-15 2007-04-11 University of Washington Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
US6264994B1 (en) * 1997-05-15 2001-07-24 University Of Washington Compositions for treating alzheimer's disease and other amyloidoses
US6929808B2 (en) * 2000-11-03 2005-08-16 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants

Also Published As

Publication number Publication date
US7754250B2 (en) 2010-07-13
DE69837551T2 (de) 2007-12-20
JP2002508752A (ja) 2002-03-19
US20040076698A1 (en) 2004-04-22
ATE359071T1 (de) 2007-05-15
EP1019044B1 (de) 2007-04-11
US20010055630A1 (en) 2001-12-27
EP1019044A4 (de) 2004-01-07
US6939570B1 (en) 2005-09-06
CA2289531A1 (en) 1998-11-19
ES2285772T3 (es) 2007-11-16
JP4386470B2 (ja) 2009-12-16
US20040086585A1 (en) 2004-05-06
US20080206162A1 (en) 2008-08-28
US6607758B2 (en) 2003-08-19
AU7580098A (en) 1998-12-08
CA2289531C (en) 2009-09-29
US7029710B2 (en) 2006-04-18
WO1998051302A1 (en) 1998-11-19
EP1019044A1 (de) 2000-07-19
DK1019044T3 (da) 2007-08-06

Similar Documents

Publication Publication Date Title
ATE359071T1 (de) Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
ATE17079T1 (de) Praeparat zur behandlung von wunden der hautoberflaeche und verfahren zur herstellung des praeparats.
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69006684T2 (de) Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69931159D1 (de) Antimikrobielle zusammensetzungen enthaltend taurolidin, zitronensäure und natriumzitrat
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
ATE71629T1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
AU1870097A (en) Use of a medicament and use of mixture of substances to produce a medicament
DE69516110T2 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
ATE251911T1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69622704T2 (de) Pharmazeutische zusammensetzungen zur behandlung von alkoholsucht
ATE131729T1 (de) 3,5-diiod-l-thyronin zur tsh-suppression und behandlung von struma
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
FR2592043A1 (fr) 2-chloro-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo-(d, g) (1, 3, 6)-dioxazocines optiquement actives, procede pour leur preparation et compositions pharmaceutiques les contenant
JPH02117618A (ja) 火傷治療薬

Legal Events

Date Code Title Description
8364 No opposition during term of opposition